Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Akebia Therapeutics (AKBA) Leases (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Leases for 7 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases fell 55.43% to $3.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.7 million, a 55.43% decrease, with the full-year FY2025 number at $3.7 million, down 55.43% from a year prior.
  • Leases was $3.7 million for Q4 2025 at Akebia Therapeutics, down from $4.8 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $33.9 million in Q4 2021 to a low of $3.7 million in Q4 2025.
  • A 5-year average of $18.0 million and a median of $13.9 million in 2023 define the central range for Leases.
  • Peak YoY movement for Leases: soared 30.81% in 2022, then tumbled 59.23% in 2024.
  • Akebia Therapeutics' Leases stood at $33.9 million in 2021, then dropped by 13.87% to $29.2 million in 2022, then tumbled by 57.42% to $12.4 million in 2023, then crashed by 33.81% to $8.2 million in 2024, then crashed by 55.43% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Leases are $3.7 million (Q4 2025), $4.8 million (Q3 2025), and $6.0 million (Q2 2025).